Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Video Interview: 'More Out-Licensing Divestment Expected In 2016,' Says AZ's Grady

This article was originally published in Scrip

Executive Summary

AstraZeneca PLC's head of strategic partnering and business development, Shaun Grady, tells Pharma Intelligence senior editor Sten Stovall that Britain's second-biggest drug maker remains committed to developing medicines across small molecules, biologics, vaccines, protein engineering and devices and that's what its future targeted business development strategy will pursue. AstraZeneca has recently been selling mature products to buyers in efforts to focus on its central activities while also unlocking value from medicines in its portfolio, a recent example being the sale in March of rights to opioid-induced constipation drug Moventig (naloxegol) in the EU, as well as Iceland, Norway, Switzerland and Lichtenstein to Kyowa Hakko Kirin subsidiary ProStrakan Group. Grady makes clear in this interview that "Where there are assets we feel are more valuable in the hands of others then we will look to partner them."

You may also be interested in...

Patient-Centric: Evotec’s CSO Explains R&D Strategy

Evotec’s multimodality approach to drug discovery landed the biotech two new discovery collaborations this week, underscoring its emphasis on patient-driven data.

Novo Nordisk, Evotec Link Around Chronic Kidney Disease

Novo Nordisk and Evotec will identify and develop novel drugs for treating chronic kidney disease, using datasets of CKD patients provided by the Danish group and from other sources.

Strategic M&A: Sanofi Buys Principia Biopharma For $3.7bn

Sanofi is paying for $3.68bn cash for Principia to get the US biotech’s drug development platform and nascent pipeline, including a brain-penetrant BTK inhibitor in Phase III for multiple sclerosis.





Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts